
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/no-government-money-no-problem-for-moderna-and-pfizer-11656327781
Listen to article
(2 minutes)
A Food and Drug Administration committee will meet Tuesday to discuss how to move forward with the next generation of vaccines ahead of a booster campaign this fall. Paying for them is another matter.
Congress has so far failed to approve additional funding for the shots—bad news for the U.S. population at large, but not bad at all for vaccine makers. They will just charge higher prices in the private market. The White House already is preparing to ration its vaccine supply to the most vulnerable Americans, according to White House coronavirus coordinator Dr. Ashish Jha. For Moderna the first manufacturer to release data for an updated vaccine based on the Omicron variant of Covid-19, this could herald a new phase of the pandemic.
Continue reading your article witha WSJ membership
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
WSJ Membership
Customer Service
Tools & Features
Ads
More
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

